目的 觀察貝那普利聯(lián)合左卡尼汀治療擴張型心肌病心力衰竭的臨床療效。方法 選取2015年10月-2016年9月鄭州市骨科醫(yī)院收治的擴張型心肌病心力衰竭患者86例，隨機分為對照組和治療組，每組各43例。對照組患者靜脈滴注左卡尼汀注射液，3 g/次，1次/d；治療組在對照組的基礎(chǔ)上口服鹽酸貝那普利片，10 mg/次，1次/d。兩組患者均治療2周。評價兩組患者臨床療效，同時比較治療前后兩組患者6 min步行距離、明尼蘇達心力衰竭生活質(zhì)量表評分（MLHFQ）、心臟彩超、高敏C反應(yīng)蛋白（hs-CRP）和N末端B型鈉尿肽原（NT-proBNP）水平改善情況。結(jié)果 治療后，對照組和治療組總有效率分別為76.74%、88.37%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者6 min步行距離明顯增加，MLHFQ評分明顯降低，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者6 min步行距離顯著大于對照組，MLHFQ評分顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者LVESD和LVEDD均顯著降低，LVEF顯著升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者LVESD、LVEDD、LVEF改善程度均比對照組更明顯（P<0.05）。治療后，兩組患者hs-CRP和NT-proBNP水平均顯著降低（P<0.05）；且治療后治療組患者hs-CRP和NT-proBNP水平顯著低于對照組（P<0.05）。結(jié)論 貝那普利聯(lián)合左卡尼汀治療擴張型心肌病心力衰竭效果明顯，臨床癥狀以及檢查化驗指標改善明顯，不良反應(yīng)較少，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical curative effect of benazepril combined with levocarnitine in treatment of dilated cardiomyopathy heart failure. Methods Patients (86 cases) with dilated cardiomyopathy heart failure in Zhengzhou Orthopaedics Hospital from October 2015 to September 2016 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Levocarnitine Injection, 3 g/time, once daily. Patients in the treatment group were po administered with Benazepril Hydrochloride Tablets on the basis of the control group, 10 mg/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, clinical efficacy was evaluated, and the improvement of 6 min walking distance, MLHFQ scores, color Doppler ultrasound, hs-CRP, and NT-proBNP levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.74% and 88.37%, respectively, and there were differences between two groups (P<0.05). After treatment, the 6 min walking distance in two groups was significantly increased, but MLHFQ scores were significantly decreased, and the difference was statistically significant in the same group (P<0.05). The 6 min walking distance in the treatment group was significantly longer than that in the control group, and MLHFQ scores was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the LVESD and LVEDD in two groups were significantly decreased, but LVEF was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of LVESD, LVEDD, and LVEF in the treatment group was more significant than those in the control group, with significant difference between two groups (P<0.05). After treatment, the hs-CRP and NT-proBNP levles in two groups were significantly decreased (P<0.05). And the hs-CRP and NT-proBNP levels in treatment group were significantly lower than those in the control group (P<0.05). Conclusion Benazepril combined with levocarnitine has an obvious clinical curative effecst in treatment of dilated cardiomyopathy heart failure, clinical symptoms and laboratory examination indexes were significantly improved with less adverse reactions, which has a certain clinical application value.